RecruitingNCT06073834

LUNG INFECTION in ICU (LUNG-I3)

LUNG INFECTION in ICU

Sponsor

BioMérieux

Enrollment

68 participants

Start Date

Dec 5, 2023

Study Type

OBSERVATIONAL

Conditions

VAP - Ventilator Associated Pneumonia

Summary

objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils

Eligibility

Min Age: 18 Years

Inclusion Criteria8

All the following criteria
Age 18 years or greater
Severe ICU patients hospitalized for one of the above diseases:
Septic shock (requirement of vasopressor to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (\>18 mg/dL) in the absence of hypovolemia) caused either by pneumonia (n=20) or another source n=20)
Severe trauma (level I and II), Injury Severity Score ≥ 25 OR
Burn with TBSA over 20%
NAD \> 0.1 µg/kg/min
At least 2 SOFA criteria ≥ 2 points

Exclusion Criteria13

Aspiration pneumonia
Unable to obtain a valid and written consent from a patient or their legally authorized representative in accordance with the local regulatory instances (this includes in FR: Person not affiliated to a health insurance scheme, or not a beneficiary of such a scheme. Persons who are the subject of a legal protection order. Person with restricted freedom following a legal or administrative decision and a person admitted without their consent pursuant to Articles L.3212-1 and 3213-1, which are not included in Article L.1121-8 of the French Public Health Code.)
COPD
Smoke inhalation in burn patients
Participation in an intervention study
Pregnant or breastfeeding women
Immunocompromised patients, defined as
patients with solid tumors with chemotherapy in the last 3 months or a progressive metastatic disease
hematologic malignancies
solid organ transplantation
HIV infection with or without AIDS
treatment with corticosteroids (\> 3 months at any dosage or ≥ 1 mg/kg prednisone equivalent per day for \> 7 day)
treatment with other immunosuppressive drugs.